Takeda invests CA$7.5m in Structural Genomics Consortium to fund collective drug research

Published: 7-Dec-2015

Renewing a partnership that started in 2012

Japanese pharmaceutical firm Takeda has renewed its partnership with the Structural Genomics Consortium (SGC) to fund collective drug research aimed at bringing new medicines to patients faster. Takeda has invested an additional CA$7.5m, adding to its initial investment in 2012 of CA$5m.

SGC is an open-source collaboration of more than 200 scientists from academia and industry working on pre-competitive, human biology and early-stage drug research, the results of which are available openly to the whole scientific community.

The Consortium is based at the University of Toronto, Canada, operating from the MaRS Discovery District, and at the Universities of Campinas (Brazil), North Carolina (Chapel Hill, US) and Oxford (UK).

'Takeda is pleased to expand its investment in the Structural Genomics Consortium as a testament both to the excellent work being done by all the scientists involved and the collaborative nature of this basic research,' said Tetsuyuki Maruyama, General Manager & Head of the Pharmaceutical Research Division, Takeda Pharmaceutical and member of the Board of Directors of the SGC.

SGC is funded by Abbvie, Bayer, Boehringer Ingelheim, Canada Foundation for Innovation, Eli Lilly Canada, Genome Canada, GlaxoSmithKline, Janssen, Merck Canada, Novartis, Ontario Ministry of Research & Innovation, Pfizer, Takeda, and the Wellcome Trust.

You may also like